|
MechanismRespiratory syncytial virus F protein inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. |
First Approval Date31 Oct 2022 |
|
MechanismSMPD1 inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.JP |
First Approval Date28 Mar 2022 |
|
Mechanismα-glucosidase stimulants |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date06 Aug 2021 |
A multi-center, prospective, longitudinal cohort study of Chlamydia trachomatis infection and reinfection in adults aged 18 to 29 years.
A randomized, placebo-controlled, sequential, participant- and Investigator-masked Phase 1 study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics ( PD) of ascending single and multiple doses of SAR446422 in female and male healthy participants 18 to 55 years of age
A randomized, double-blind, placebo-controlled, phase 1, single centre, First-in-human, two-part study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of single (SAD17442) and multiple (MAD17443) ascending, subcutaneous doses of SAR444559 in healthy adult participants.
100 Clinical Results associated with Sanofi-Aventis Australia Pty Ltd.
0 Patents (Medical) associated with Sanofi-Aventis Australia Pty Ltd.
100 Deals associated with Sanofi-Aventis Australia Pty Ltd.
100 Translational Medicine associated with Sanofi-Aventis Australia Pty Ltd.